RT Journal Article
SR Electronic
T1 Donor clonal hematopoiesis and recipient outcomes after transplantation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.25.21263697
DO 10.1101/2021.09.25.21263697
A1 Gibson, Christopher J.
A1 Kim, Haesook T.
A1 Zhao, Lin
A1 Murdock, H. Moses
A1 Hambley, Bryan
A1 Ogata, Alana
A1 Madero-Marroquin, Rafael
A1 Wang, Shiyu
A1 Green, Lisa
A1 Fleharty, Mark
A1 Dougan, Tyler
A1 Cheng, Chi-An
A1 Blumenstiel, Brendan
A1 Cibulskis, Carrie
A1 Tsuji, Junko
A1 Duran, Madeleine
A1 Gocke, Christopher D.
A1 Antin, Joseph H.
A1 Nikiforow, Sarah
A1 DeZern, Amy E.
A1 Chen, Yi-Bin
A1 Ho, Vincent T.
A1 Jones, Richard J.
A1 Lennon, Niall J.
A1 Walt, David R.
A1 Ritz, Jerome
A1 Soiffer, Robert J.
A1 Gondek, Lukasz P.
A1 Lindsley, R. Coleman
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.09.25.21263697.abstract
AB Clonal hematopoiesis (CH) can be transmitted from donor to recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain.Methods We performed targeted error-corrected sequencing on samples from 1727 donors aged 40 or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and cytokine levels in 256 recipients at 3 and 12 months after transplant.Results CH was present in 22.5% of donors, with DNMT3A (14.6%) and TET2 (5.2%) mutations being most common; 85% of donor clones showed engraftment in recipients after transplantation, including clones with variant allele fraction (VAF)<0.01. DNMT3A-CH with VAF≥0.01, but not smaller clones, was associated with improved recipient overall (HR 0.79, P=0.042) and progression-free survival (HR 0.72, P=0.003) after adjustment for significant clinical variables. In patients receiving calcineurin-based GVHD prophylaxis, donor DNMT3A-CH was associated with reduced relapse (sHR 0.59, P=0.014), increased chronic GVHD (sHR 1.36, P=0.042), and higher IL-12p70 levels in recipients. No recipient of sole DNMT3A or TET2-CH developed donor cell leukemia (DCL). In 7 of 8 cases, DCL evolved from donor CH with rare TP53 or splicing factor mutations or from donors carrying germline DDX41 mutations.Conclusion Donor CH is associated with clinical outcomes in transplant recipients, with differential impact on alloimmune function and potential for leukemic transformation related to mutated gene and clonal abundance. DNMT3A-CH is associated with improved recipient survival due to reduced relapse risk and an augmented network of inflammatory cytokines in recipients. Risk of DCL is driven by pre-existing somatic MDS-associated mutations or germline predisposition in donors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health K08CA204734 (RCL), P01CA229092 (RCL, JR, RJS), K08HL136894 (LPG), R01HL156144 (LPG), Damon Runyon Cancer Research Foundation (CJG), the Alan and Lisa Dynner Fund (RS, RCL), the James A. and Lois J. Champy Family Fund (RCL), the Jock and Bunny Adams Education and Research Fund (JHA)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with approval of the Dana-Farber Cancer Institute IRB (protocol #16-582) and the Johns Hopkins University IRB (IRB00141250)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all genetic data supporting the findings of this study are available within the paper and the supporting supplementary materials. Deidentified clinical and genomic data are available from the corresponding author upon reasonable request.